Aldafermin (NGM282) for Chronic Diarrhea Due to Bile Acid Malabsorption (BAM)
Status:
Not yet recruiting
Trial end date:
2023-01-01
Target enrollment:
Participant gender:
Summary
This single-center, randomized, double-blind, placebo-controlled study is designed to compare
effects of aldafermin, (NGM282), 1 mg, and placebo given daily by subcutaneous injection on
bowel functions and hepatic synthesis and fecal excretion of bile acids in patients with
diarrhea associated with bile acid malabsorption (BAM).